N-[2,6-Bis(1-methylethyl)phenyl]-N'-[4-[(4-nitrophenyl)thio]phenyl]urea manufacturers
- VULM 1457
-
- $41.00
-
2026-05-11
- CAS:228544-65-8
- Purity: 99.92%
- Supply Ability: 10g
|
| | N-[2,6-Bis(1-methylethyl)phenyl]-N'-[4-[(4-nitrophenyl)thio]phenyl]urea Basic information |
| Product Name: | N-[2,6-Bis(1-methylethyl)phenyl]-N'-[4-[(4-nitrophenyl)thio]phenyl]urea | | Synonyms: | VULM 1457;VULM 1457,acyl-CoA:cholesterol acyltransferase,hypercholesterolaemia,Diacylglycerol acyltransferase,ischaemia-reperfusion,myocardial,Diglyceride acyltransferase,mono- acylglycerol acyltransferase,Inhibitor,VULM1457,acyl-CoA,cholesterol acyltransferase,Acyltransferase,hypolipidaemic,inhibit,VULM-1457,diabetes mellitus;Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[4-[(4-nitrophenyl)thio]phenyl]-;1-(2,6-Diisopropylphenyl)-3-(4-((4-nitrophenyl)thio)phenyl)urea;N-[2,6-Bis(1-methylethyl)phenyl]-N'-[4-[(4-nitrophenyl)thio]phenyl]urea | | CAS: | 228544-65-8 | | MF: | C25H27N3O3S | | MW: | 449.57 | | EINECS: | | | Product Categories: | | | Mol File: | 228544-65-8.mol | ![N-[2,6-Bis(1-methylethyl)phenyl]-N'-[4-[(4-nitrophenyl)thio]phenyl]urea Structure](CAS/GIF/228544-65-8.gif) |
| | N-[2,6-Bis(1-methylethyl)phenyl]-N'-[4-[(4-nitrophenyl)thio]phenyl]urea Chemical Properties |
| Boiling point | 535.0±50.0 °C(Predicted) | | density | 1.24±0.1 g/cm3(Predicted) | | storage temp. | Store at +4°C | | solubility | Soluble to 100 mM in DMSO | | form | Powder | | pka | 13.79±0.70(Predicted) | | color | Light yellow to yellow |
| | N-[2,6-Bis(1-methylethyl)phenyl]-N'-[4-[(4-nitrophenyl)thio]phenyl]urea Usage And Synthesis |
| Uses | VULM 1457 is a cholesterol acyltransferase inhibitor. | | Biological Activity | Acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor. Decreases cholesterol levels in the plasma and liver of diabetic-hypercholesterolaemic rats. | | in vivo | VULM 1457 significantly reduces atherogenic activity in animal experimental atherosclerosis[1].
VULM 1457 protect the hearts of diabetic–hypercholesterolaemic rats against ischaemia/reperfusion injury in vivo[2].
VULM 1457 (50 mg/kg/day; administered as an admixture to the fat-cholesterol diet for 5 days) significantly decreases plasma total cholesterol levels (1.7±0.1 mM vs. 2.9±0.5 mM in diabetic–hypercholesterolaemic animals). The hypolipidaemic effect of VULM 1457 is also observed in the liver of DM-HCH rats (3.9±0.2 mg/g vs. 7.4±1.0 mg/g)[2]. | Animal Model: | Male Wistar rats (250-300 g body weight), fed a standard diet and tap water ad libitum[2] | | Dosage: | 50 mg/kg/day | | Administration: | Administered as an admixture to the fat-cholesterol diet for 5 days | | Result: | Improved the overall myocardial ischaemia-reperfusion injury outcomes in the diabetic-hypercholesterolaemic rats by suppressing arrhythmogenesis as well as by reducing myocardial necrosis, aside from remarkable hypolipidaemic activity. |
| | IC 50 | ACAT |
| | N-[2,6-Bis(1-methylethyl)phenyl]-N'-[4-[(4-nitrophenyl)thio]phenyl]urea Preparation Products And Raw materials |
|